1199.26 study of BIBF vs sunitinib in RCC.

• Research type

  Research Study

• Full title

  A randomised, open label, parallel group Phase II study comparing the efficacy and tolerability of BIBF 1120 versus sunitinib in previously untreated patients with Renal Cell Cancer.

• IRAS ID

  9100

• Contact name

  Timothy Eisen

• Eudract number

  2009-009516-44

• ISRCTN Number

  n.a

• Clinicaltrials.gov Identifier

  n.a

• Research summary

  The 1199.26 study is designed to compare how effective and safe two drugs, BIBF 1120 and sunitinib (Sutent©), are in treating adult patients kidney cancer (Renal Cell Cancer - RCC). In addition, the study will investigate the effect of BIBF 1120 on cardiac function, in particular QTc changes.

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  09/H0305/84

• Date of REC Opinion

  27 Oct 2009

• REC opinion

  Further Information Favourable Opinion